QC violations raised by FDA at another Aurobindo site
Generic drug manufacturer Aurobindo Pharma has received another 483 inspection report from the FDA, this time with quality concerns, particularly in response to customer complaints.
The 17-page report gives the details of an inspection conducted by the FDA at Aurobindo’s active pharmaceutical ingredient (API) manufacturing facility in Hathnoora, India, with a total of 10 observations being noted by the US regulator.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.